SPOTIFY
Today Spotify (NYSE: SPOT) launches its service in South Korea, giving Korean listeners access to over 60 million tracks and over 4 billion playlists from around the world. As the world’s most popular audio streaming subscription service, Spotify offers an effortlessly simple interface, an innovative technology framework, everyday new music discovery and algorithmic recommendations personalized to each listener’s music taste. This launch brings Spotify’s total number of markets to 93.
As the sixth-largest music market in the world*, South Korea is a critical next step in Spotify’s global expansion journey. Not only is South Korea among the most digitally inclusive markets in the world, but it is also widely recognized as a cultural and music epicenter, in part due to the global phenomena K-Pop. Since Spotify debuted its first K-Pop playlist in 2014, the share of K-Pop listening on the platform has increased by more than 2,000%. With this launch, Spotify plans to accelerate the growth of Korea’s entire music streaming ecosystem, benefitting creators, labels, distributors and fans.
“We always want to be where the listeners and artists are, and Korea is rich in both,” said Alex Norström, Chief Freemium Business Officer of Spotify. “This launch presents a massive opportunity for us to not only further our mission of bringing new and quality content to more audiences, but also help local Korean artists tap into Spotify’s 320 million listeners worldwide. We hope to create more opportunities for Korean artists across all genres to be discovered by listeners around the world.”
Spotify has uniquely tailored the music experience for each market. As a part of today’s launch, Spotify is introducing a range of new playlists made exclusively for South Korea. These playlists offer curated and the latest music from our team of Korean music experts, across some of the most popular genres. These include:
- TOP Playlists: Korean Music Hot Now , FRESH! New Music Korea , Hot Hits Korea , Korean Music Rising , Today's Drama OST Hot Now , K-Pop Daebak and more
- Genre Playlists : TrenChill K-R&B , TrenChill K-Hip Hop , K-HIP-HOP +82 , K-Are & Be , In The K-Indie , Korean City Pop , K-Rock Spirit , Folk & Acoustic Hot Now , Orchestra Korean Ballad and more
- Thematic Playlists : You Did Well , The End of the Day , So Cool Driving , Brain Rest 432Hz , Lullaby zZZ , Transcendental Game Play , Running K-Pop , GAYO Instrumentals , Spring Music , Into the Rain , Next Page of the Break-up , Kitchen Melodies and more
- ‘Starring’ playlists : This Is BTS , This Is BLACKPINK , This Is Stray Kids , This Is NCT , This Is TWICE , This is Taeyeon , This Is JAY Park , This Is CHUNG HA , This Is Loco and more
These new playlists will join Spotify’s K-Pop genre hub that encompasses a wide range of Korean music, including K-pop, Hip Hop, Indie, OST, R&B and more, as well as ‘RADAR Korea’, a playlist uncovering fresh K-music finds and a part of Spotify’s global emerging artist program. The hub is localized in over 72 countries, including Russia, India, Brazil and the UAE.
In Korea, new listeners can try out Spotify Premium 7 days-free on their mobile phone with no credit card information and a total of 3 months-free with credit card information, if subscribed before the end of June 2021. Listeners can engage with Spotify across a wide range of devices and app integrations including Instagram, Facebook, Samsung mobile and TV, LG TV, Microsoft Xbox, Bose and more.
The Spotify app is available to download for both Premium Individual and Duo plans. To enjoy music the way you want it, download the Spotify app today via the Android or iOS app store or by heading to www.spotify.com/kr-ko/ .
Click here for further imagery.
* According to IFPI (https://www.ifpi.org/wp-content/uploads/2020/07/Global_Music_Report-the_Industry_in_2019-en.pdf )
About Spotify Technology S.A.
Spotify transformed music listening forever when we launched in 2008. Our mission is to unlock the potential of human creativity by giving a million creative artists the opportunity to live off their art and billions of fans the opportunity to enjoy and be inspired by these creators.
Today, with over 60 million tracks and over 4 billion playlists, we are the world’s most popular audio streaming subscription service with a community of more than 320 million listeners across 93 markets.
We use our Investors and For the Record websites as well as other social media listed in the “Resources – Social Media” tab of our Investors website to disclose material company information. For more information, images, or to contact the press team, head over to https://newsroom.spotify.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005846/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom